Can intrathecal therapy improve neurological outcomes for leptomeningeal metastasis?
Leptomeningeal metastasis (LM) means cancer has spread into the fluid and thin layers that surround the brain and spinal cord. It is a serious complication, and the goal of treatment is to slow neurological decline and maintain quality of life 6. Intrathecal therapy delivers drugs directly into the cerebrospinal fluid (CSF), the fluid around the brain and spine, bypassing the blood-brain barrier that blocks many systemic drugs 25. The short answer: yes, intrathecal therapy can improve neurological outcomes for some patients, but response rates vary widely and the evidence comes mostly from lung cancer studies and case reports, not large trials across all cancer types.
What the research says
A systematic review of 12 clinical studies with 544 patients with non-small-cell lung cancer (NSCLC) and LM found that intrathecal therapy produced objective response rates of 34.5% to 86.4% and disease control rates of 62.5% to 94.9% 2. Median overall survival ranged from 3.66 to 17 months, and common side effects included myelosuppression (bone marrow suppression), gastrointestinal problems, and neurological symptoms 2. A separate systematic review of Ommaya reservoir-based intrathecal therapy in NSCLC-related LM notes that the Ommaya reservoir, an implantable device that delivers drugs into the fluid-filled spaces of the brain, helps achieve therapeutic drug concentrations in the CSF 58. These reviews show that intrathecal treatment can control the disease in a meaningful share of patients, though the range of responses is broad.
What to ask your doctor
- Does my type of cancer and my LM diagnosis make intrathecal therapy a reasonable option for me?
- What are the expected benefits and risks of intrathecal therapy compared with systemic therapy or radiotherapy for my situation?
- Would an Ommaya reservoir or lumbar puncture be used to deliver the treatment, and what are the pros and cons of each?
- What neurological symptoms should I watch for that might mean the treatment is or is not working?
- Are there clinical trials or newer intrathecal agents (such as targeted therapies or immunotherapy) that might apply to my cancer type?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.